ACADIA Pharmaceuticals Inc. (ACAD)

26.10
NASDAQ : Health Technology
Prev Close 27.22
Day Low/High 25.97 / 27.38
52 Wk Low/High 12.77 / 28.12
Avg Volume 1.69M
Exchange NASDAQ
Shares Outstanding 143.88M
Market Cap 3.92B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
ACADIA PHARMACEUTICALS SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against ACADIA Pharmaceuticals Inc.

First Week Of October 19th Options Trading For Acadia Pharmaceuticals (ACAD)

First Week Of October 19th Options Trading For Acadia Pharmaceuticals (ACAD)

Investors in Acadia Pharmaceuticals Inc saw new options begin trading this week, for the October 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new October 19th contracts and identified one put and one call contract of particular interest.

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results

ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Acadia Pharmaceuticals, Inc.

ACADIA Pharmaceuticals And Neuren Pharmaceuticals Announce Exclusive License Agreement For The North American Development And Commercialization Of Trofinetide In Rett Syndrome

ACADIA Pharmaceuticals And Neuren Pharmaceuticals Announce Exclusive License Agreement For The North American Development And Commercialization Of Trofinetide In Rett Syndrome

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that they have entered into an exclusive North American License Agreement for the development and commercialization of trofinetide for Rett syndrome...

ACAD ALERT NOTICE: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.; Investor Deadline - ACAD

ACAD ALERT NOTICE: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.; Investor Deadline - ACAD

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ACADIA Pharmaceuticals Inc.

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds that an investor securities fraud class action lawsuit has been filed against ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals To Announce Second Quarter 2018 Financial Results On August 8, 2018

ACADIA Pharmaceuticals To Announce Second Quarter 2018 Financial Results On August 8, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its...

KASKELA LAW LLC: Shareholder Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

KASKELA LAW LLC: Shareholder Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against ACADIA Pharmaceuticals Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Acadia Pharmaceuticals, Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Acadia Pharmaceuticals, Inc.

Federman & Sherwood announces that on July 19, 2018, a class action lawsuit was filed in the United States District Court for the Southern District of California against Acadia Pharmaceuticals, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ACADIA Pharmaceuticals Inc.

Austin D. Kim, Executive Vice President, General Counsel And Secretary (Photo: Business Wire)

Austin D. Kim, Executive Vice President, General Counsel And Secretary (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Austin D.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against ACADIA Pharmaceuticals Inc. - ACAD

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against ACADIA Pharmaceuticals Inc. - ACAD

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of ACADIA Pharmaceuticals Inc.

August 24th Options Now Available For Acadia Pharmaceuticals (ACAD)

August 24th Options Now Available For Acadia Pharmaceuticals (ACAD)

Investors in Acadia Pharmaceuticals Inc saw new options begin trading today, for the August 24th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new August 24th contracts and identified one put and one call contract of particular interest.

NUPLAZID® (pimavanserin) Bottle (Photo: Business Wire)

NUPLAZID® (pimavanserin) Bottle (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced FDA approval of a new capsule dose formulation and a new tablet strength of NUPLAZID (pimavanserin) to help in the treatment of patients living with hallucinations and delusions associated with...

ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 20, 2018

ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 20, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

ACADIA Pharmaceuticals To Present At The Goldman Sachs 39th Annual Global Healthcare Conference On June 13, 2018

ACADIA Pharmaceuticals To Present At The Goldman Sachs 39th Annual Global Healthcare Conference On June 13, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

3 Biotech Best Bets From the 'Stock Picker of the Year'

3 Biotech Best Bets From the 'Stock Picker of the Year'

In 2017, McCamant's model portfolio rose 65%, while his trader's portfolio rose 98%.

First Week Of July 20th Options Trading For Acadia Pharmaceuticals (ACAD)

Investors in Acadia Pharmaceuticals Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch Health Care Conference 2018

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch Health Care Conference 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results

ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial...

Elena Ridloff, CFA, Senior Vice President, Investor Relations (Photo: Business Wire)

Elena Ridloff, CFA, Senior Vice President, Investor Relations (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Elena Ridloff,...

ACADIA Pharmaceuticals To Announce First Quarter 2018 Financial Results On May 4, 2018

ACADIA Pharmaceuticals To Announce First Quarter 2018 Financial Results On May 4, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its...

ACADIA Pharmaceuticals Announces Presentation Of Clinical Experience Data For NUPLAZID (Pimavanserin) At 2018 American Academy Of Neurology (AAN) Annual Meeting

ACADIA Pharmaceuticals Announces Presentation Of Clinical Experience Data For NUPLAZID (Pimavanserin) At 2018 American Academy Of Neurology (AAN) Annual Meeting

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced poster presentations...

ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile Of NUPLAZID

ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile Of NUPLAZID

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today issued the following statement: NUPLAZID ® (pimavanserin) is the only medicine approved in the United States to treat hallucinations and delusions associated with Parkinson's disease psychosis.

June 8th Options Now Available For Acadia Pharmaceuticals (ACAD)

Investors in Acadia Pharmaceuticals Inc saw new options become available today, for the June 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new June 8th contracts and identified the following call contract of particular interest.

PMDAlliance And ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact Of Non-Movement Symptoms Of Parkinson's Disease

PMDAlliance And ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact Of Non-Movement Symptoms Of Parkinson's Disease

As part of Parkinson's Disease Awareness Month, the Parkinson & Movement Disorder Alliance (PMDAlliance) and ACADIA Pharmaceuticals Inc.

Lennar, LG Homes, GrubHub, Sprint: 'Mad Money' Lightning Round

Lennar, LG Homes, GrubHub, Sprint: 'Mad Money' Lightning Round

Jim Cramer looks at Lennar, LG Homes, GrubHub, Sprint, Acadia Pharmaceuticals, Pilgrim's Pride, Opko Health and more.